$エスペリオン・セラピューティクス(ESPR.US)$Esperion (ESPR) stock price has dropped from a recent high of $3.40 a share to $2.31 on FALSE claims of dilution. The price drop offers an amazing buying opportunity. Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
$エスペリオン・セラピューティクス(ESPR.US)$Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo – – NEXLETOL Demonstrated Clinical Benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients With and Without Cardiovascular Disease (CVD) – – CLEAR Outcomes Sets New Standards for Diversity and Inclusion ...
$エスペリオン・セラピューティクス(ESPR.US)$Not worried unless it drops below 2.63? If that happens 2.12 could be possible? But for now after the uptrend its been on, im just looking at is as a bit of a pullback! Especially with the amount of shares sold short just today! Lit exchange alone over 1 million! Not counting the ones routed to DP! JMO
$エスペリオン・セラピューティクス(ESPR.US)$ HOT NEWS ON OBESITY STUDY Esperion (Nasdaq: ESPR) presented positive results from the CLEAR Outcomes trial at the 2024 American College of Cardiology’s Annual Scientific Sessions. Patients with obesity on NEXLETOL had a 23% lower risk of MACE-4 compared to placebo. The trial highlighted benefits in women and Hispanic/Latinx patients, emphasizing the importance of early LDL-C lowering for reducing cardiovascular events.
エスペリオン・セラピューティクスに関するコメント
it's going down?
ESPR is the Probably the Most Undervalued Stock on the Market, Offers 2500% Upside. 2 FDA Approved Blockbuster Drugs. Billions in Sales Expected. Buyout Expected.
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
Diggin the reversal
Hmm? Weight loss with DEI kicker and it’s down! Hehehe! I get it today is Opposite Day! Hehehe!
– NEXLETOL Demonstrated Clinical Benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients With and Without Cardiovascular Disease (CVD) –
– CLEAR Outcomes Sets New Standards for Diversity and Inclusion ...
game over
HOT NEWS ON OBESITY STUDY
Esperion (Nasdaq: ESPR) presented positive results from the CLEAR Outcomes trial at the 2024 American College of Cardiology’s Annual Scientific Sessions. Patients with obesity on NEXLETOL had a 23% lower risk of MACE-4 compared to placebo. The trial highlighted benefits in women and Hispanic/Latinx patients, emphasizing the importance of early LDL-C lowering for reducing cardiovascular events.
is this brewing ?
まだコメントはありません